UCB and Biogen Idec discontinue Phase II clinical trial of CDP323
Preliminary interim efficacy analysis showed no clinically relevant benefit for patients
CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis.
For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.